MedPath

Het vaststellen van botmetastases in hormoon naïeve prostaatkanker in PET/CT met behulp van [18F]FDHT

Conditions
hormone naive prostate cancer metastasized to bone, hormoon naïve bot-gemetastaseerde prostaatkanker
Registration Number
NL-OMON27460
Lead Sponsor
MCG
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Other
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

•metastasized prostate cancer, ≥2 lesions in bone, confirmed by

ovisible lesions on bone scan, CT and/or MRI consistent with disease

Exclusion Criteria

•active cancer besides prostate cancer

•age < 50 years

Study & Design

Study Type
Observational non invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Patients with metastasized prostate cancer will undergo a [18F]FDHT PET/CT before start of ADT. A second scan will be performed three months after start of ADT.<br>Primary outcome is the amount of decreased uptake of 18F-FDHT per lesions before and after three months of ADT.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath